Your browser doesn't support javascript.
loading
A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg, Kristin A; Viswanadhapalli, Suryavathi; Mann, Monica; Chakravarty, Dimple; Krishnan, Samaya; Liu, Zexuan; Liu, Junhao; Pratap, Uday P; Ebrahimi, Behnam; Sanchez, John R; Li, Xiaonan; Ma, Shihong; Park, Ben H; Santhamma, Bindu; Chen, Yidong; Lai, Zhao; Raj, Ganesh V; Yuan, Yaxia; Zhou, Daohong; Sareddy, Gangadhara R; Tekmal, Rajeshwar R; McHardy, Stan; Huang, Tim H-M; Rao, Manjeet K; Vankayalapati, Hariprasad; Vadlamudi, Ratna K.
Afiliação
  • Altwegg KA; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Viswanadhapalli S; Mays Cancer Center, UT Health San Antonio, San Antonio, Texas.
  • Mann M; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Chakravarty D; Mays Cancer Center, UT Health San Antonio, San Antonio, Texas.
  • Krishnan S; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Liu Z; Department of Urology, Weill Cornell Medical School, New York, New York.
  • Liu J; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Pratap UP; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Ebrahimi B; Department of Oncology, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, P.R. China.
  • Sanchez JR; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Li X; Department of Oncology, Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, P.R. China.
  • Ma S; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Park BH; Mays Cancer Center, UT Health San Antonio, San Antonio, Texas.
  • Santhamma B; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Chen Y; Mays Cancer Center, UT Health San Antonio, San Antonio, Texas.
  • Lai Z; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Raj GV; Department of Obstetrics and Gynecology, UT Health San Antonio, San Antonio, Texas.
  • Yuan Y; Department of Urology, UT Southwestern Medical Center, Dallas, Texas.
  • Zhou D; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Sareddy GR; Evestra.Inc, San Antonio, Texas.
  • Tekmal RR; Department of Population Health Sciences, UT Health San Antonio, San Antonio, Texas.
  • McHardy S; Greehey Children's Cancer Research Institute, UT Health San Antonio, San Antonio, Texas.
  • Huang TH; Greehey Children's Cancer Research Institute, UT Health San Antonio, San Antonio, Texas.
  • Rao MK; Department of Molecular Medicine, UT Health San Antonio, San Antonio, Texas.
  • Vankayalapati H; Department of Urology, UT Southwestern Medical Center, Dallas, Texas.
  • Vadlamudi RK; Department of Biochemistry and Structural Biology, and Center for Innovative Drug Discovery, UT Health San Antonio, San Antonio, Texas.
Cancer Res ; 82(20): 3830-3844, 2022 10 17.
Article em En | MEDLINE | ID: mdl-35950923
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Neoplasias da Mama / Proteínas Correpressoras Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Neoplasias da Mama / Proteínas Correpressoras Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2022 Tipo de documento: Article